Andarine (S-4)
Early aryl propionamide SARM; anabolic with ocular side effects
Mechanism of Action
Andarine (S-4, GTx-007) is an early-generation aryl propionamide SARM that binds the androgen receptor with high affinity and tissue selectivity. It functions as a full agonist at AR in skeletal muscle and bone, promoting anabolic effects, while exhibiting partial agonist/antagonist activity in androgenic tissues (prostate, seminal vesicles). Andarine does not aromatize or undergo 5α-reduction. A notable distinguishing feature is its affinity for the visual pigment pathway — andarine can bind and temporarily alter rhodopsin-like proteins in the retina, causing a yellow-tinted vision effect in some subjects. This ocular side effect limited clinical development despite good anabolic efficacy.
Evidence Chain
Andarine (S-4)
COMPOUND
1 Research Goal
• Muscle & Tissue Growth
Evidence Strength
5 articles sourced
Knowledge Graph
(6 connections)Research Evidence
(5)Enobosarm (Ostarine / MK-2866): Evidence-Based Research Review
**Class:** SARM (Selective Androgen Receptor Modulator)
Andarine vs Ostarine: Evidence-Based Comparison
Selective Androgen Receptor Modulators (SARMs) were developed to provide the anabolic benefits of traditional steroids—such as increased muscle mass and bone density—while minimizing androgenic side effects like prostate enlargement and hair loss. Among the most researched SARMs are Andarine (S-4) a
YK-11: Evidence-Based Research Review
YK-11 (17α,20E)-17,20-[(1-methoxyethylidene)bis(oxy)]-3-oxo-19-norpregna-4,20-diene-21-carboxylic acid methyl ester is a synthetic compound classified as a Selective Androgen Receptor Modulator (SARM). Unlike traditional non-steroidal SARMs such as Ostarine or Ligandrol, YK-11 possesses a steroidal
Testolone (RAD-140): Evidence-Based Research Review
Testolone (RAD-140) is a potent, non-steroidal selective androgen receptor modulator (SARM) originally developed by Radius Health, Inc. It was designed to overcome the limitations of conventional androgen therapy, such as prostate enlargement and virilization, by exhibiting high tissue selectivity.
Andarine (S-4): Evidence-Based Research Review
Andarine (also known as S-4 or GTx-007) is an early-generation, nonsteroidal selective androgen receptor modulator (SARM) belonging to the aryl propionamide class. Developed initially for the treatment of conditions such as muscle wasting and osteoporosis, Andarine demonstrates high affinity for the
Related Compounds
Synergy & Compatibility
(5)Computational assessment of bio-regulatory compatibility with compounds sharing research goals. Scores reflect half-life alignment, receptor target overlap, and bioavailability data.
Highest Compatibility
Andarine (S-4) + Testosterone Enanthate
High Compatibility
Shared targets: androgen receptor (ar) — tissue-selective
Computational assessment based on available pharmacology data. Does not account for individual variability, dose-dependent effects, or unstudied interactions. For research use only.
Community Observations
(0)Qualitative, self-reported researcher observations. Distinct from peer-reviewed evidence — not medical advice.
No approved observations yet. Sign in to contribute.
For research use only. Not medical advice.